Abstracts tagged "quality of life"

Abstract Number: 2154 • ACR Convergence 2024
“I Have Taken Five Different Kinds of Tablets and Injections, and I Still Have Foot Pain”: An International Outcome Measures in Rheumatology (OMERACT) Qualitative Study Exploring Patient Perspectives of Foot and Ankle Disorders
Lara Chapman¹, Caroline Flurey², Anthony C. Redmond¹, Pam Richards³, Eiman Soliman⁴, Abdelhfeez Moshrif⁵, Lucy Malone⁶, Christopher Joyce⁷, Marian Hannan⁸, Philip S. Helliwell⁹, Catherine Hofstetter¹⁰, Hylton Menz¹¹, Beverley Shea¹² and Heidi Siddle¹, ¹University of Leeds, Leeds, United Kingdom, ²University of the West of England, Bristol, Bristol, United Kingdom, ³OMERACT, Bristol, United Kingdom, ⁴Alexandria Faculty of Medicine, Alexandria, Egypt, ⁵Al-azhar university, Assiut, Egypt, ⁶Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom, ⁷Homerton Healthcare NHS Foundation Trust, London, United Kingdom, ⁸Marcus Institute for Aging Research, Hebrew SeniorLife, Milton, MA, ⁹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ¹⁰OMERACT, Toronto, Canada, ¹¹La Trobe University, Fairfield, Victoria, Australia, ¹²Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: The foot and ankle are frequently affected in rheumatic and musculoskeletal diseases (RMDs), yet there is a lack of high-quality evidence to determine the…
Abstract Number: 0169 • ACR Convergence 2024
Impact of Sense of Control Among People Living with SLE
Amanda Eudy¹, S. Sam Lim², Charmayne M. Dunlop-Thomas³, Jinoos Yazdany⁴, Patti Katz⁵ and Laura Plantinga⁶, ¹Duke University, Raleigh, NC, ²Emory University, Atlanta, GA, ³Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁴University of California San Francisco, San Francisco, CA, ⁵UCSF, San Rafael, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: SLE is a disease characterized by cycles of remitting and relapsing symptoms that can be unpredictable, stressful, and cause an individual to feel they…
Abstract Number: 0661 • ACR Convergence 2024
Validity, Reliability and Responsiveness of Lupus Impact Tracker and LupusPRO: AURORA Trial
Meenakshi Jolly¹, Matt Truman², Ronald Flauto³ and Kathryn Dao⁴, and AURORA, ¹Rush University Medical Center, Chicago, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals, Rockville, MD, ⁴Aurinia Pharmaceuticals, Dallas
Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
Abstract Number: 1339 • ACR Convergence 2024
When Medications Fail: A Mixed Methods Study Evaluating the Experience and Health-Related Quality of Life (HRQOL) of Adults with Rheumatoid Arthritis Non-Responsive to Treatment
Kathleen Carluzzo¹, Erin Knight¹, Sidney May¹, Laura Bernstein², Kristen Mueller³, Clifton Bingham⁴ and Karen Schifferdecker¹, ¹Dartmouth College, Lebanon, NH, ²Dartmouth College, Philadelphia, PA, ³Arthritis Foundation, Washington, DC, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: RA treatment involves an iterative approach to identifying effective medications for patients. While response varies, there is little in-depth understanding of patients’ perspectives of…
Abstract Number: 2209 • ACR Convergence 2024
Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis
Michael George¹, Kelly Gavigan², Shilpa Venkatachalam³, David Curtis², Laura Stradford⁴, William Benjamin Nowell⁵, Joshua Baker¹, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Regeneron, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Serious infections are a major cause of morbidity and mortality in patients with RA, but less is known about more common, non-serious infections. We…
Abstract Number: 0204 • ACR Convergence 2024
Making Rheum for Palliative Care in Rheumatology: Perspectives of Rheumatology and Palliative Care Clinicians
Shannon Herndon¹, Jack Kimball¹, Christopher Jones¹ and David Leverenz², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Palliative care is underutilized in patients with severe rheumatic disease. We sought to describe the perspectives of rheumatology and palliative care clinicians on the…
Abstract Number: 0730 • ACR Convergence 2024
Assessment of the Quality of Life in a Single-center Cohort of Patients with ANCA-Associated Vasculitis on Targeted Therapy: Characterization of Global, Disease and Organ-specific Parameters Using Patient Reported Outcomes
Michele Moretti¹, Elena Elefante², Francesco Ferro³, Ludovica Pisapia⁴, Federica Di Cianni⁵, Nazzareno Italiano⁶, ROSARIA TALARICO⁵, Chiara Baldini⁷ and Marta Mosca⁷, ¹University of Pisa, Pisa, Pisa, Italy, ²Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁵University of Pisa, Pisa, Italy, ⁶University of Pisa, Rovigo, Italy, ⁷University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy
Background/Purpose: ANCA-associated vasculitides (AAVs) are characterized by severe and multisystemic manifestations that greatly affect patients' quality of life (QoL). The purpose of the study was…
Abstract Number: 1403 • ACR Convergence 2024
Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center
MANJIT SALUJA¹ and ARVIND CHOPRA², ¹CENTER FOR RHEUMATIC DISESAES, Pune, Maharashtra, India, ²CENTER FOR RHEUMATIC DISEASES, Pune, Maharashtra, India
Background/Purpose: Our patients often express concerns related to ‘wellbeing’ that are not routinely attended during standard care (including QOL). Alternatively, these concerns are important components…
Abstract Number: 2291 • ACR Convergence 2024
The Relationship of the ESSDAI to Health-Related Quality of Life in People Living with Sjogren’s Disease
Dana DiRenzo¹, Chadwick Johr¹, Nora Sandorfi¹, Sara McCoy² and Thomas Grader-Beck³, ¹University of Pennsylvania, Philadelphia, PA, ²University of Wisconsin, Middleton, WI, ³Johns Hopkins, Baltimore, MD
Background/Purpose: Historically, Heath Related Quality of Life (HRQL) in Sjogren’s Disease (SjD) has been measured by the EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI), which…
Abstract Number: 0245 • ACR Convergence 2024
The Impact of COVID-19 and ‘Long COVID’ on Self-Reported Disease Activity, Disability, and Quality of Life in Patients with Inflammatory Arthritis
Zachary Wallace¹, Miao Lin², Shruthi Srivatsan², Andrew King², Xiaosong Wang³, Rathnam Venkat⁴, Naomi Patel², Yumeko Kawano⁵, Abigail Schiff⁵, Jennifer Hanberg², Emily Kowalski⁵, Colebrook Johnson², Kathleen Vanni³, Zachary Williams², Grace Qian³, Caleb Bolden², Kevin Mueller⁵, Katarina Bade⁵, Alene Saavedra⁵ and Jeffrey Sparks⁶, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Tufts University School of Medicine, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: People with rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), and axial spondyloarthritis (axSpA) are at risk for poor COVID-19 outcomes, including…
Abstract Number: 0768 • ACR Convergence 2024
Addressing Gaps in Polymyalgia Rheumatica: A Systematic Literature Review
Shelley Fritz¹, Angela Degrassi², Kelly Gavigan², Ruohan Hong³, Santiago Munoz Perez², Esteban Rivera⁴, Erik Stone⁵, Laura Stradford⁶, Ambika Vartak², Anne Sydor² and Shilpa Venkatachalam³, ¹Global Healthy Living Foundation, Kalaheo, HI, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Long Island City, NY, ⁵Global Healthy Living Foundation, Upper Nyack, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: This systematic literature review on polymyalgia rheumatica (PMR) and PMR with giant cell arteritis (GCA) evaluates existing literature on disease burden, management, and treatment…
Abstract Number: 1410 • ACR Convergence 2024
Using Social Listening to Understand the Patient Voice: The Daily Impacts of Sjögren’s Disease
Zachary Cline¹, Maurice Flurie¹, Colton Flowers¹, Enming Zhang¹, Annie Lau-Kilby², Julia Taylor², Chiara Baldini³, Ilias Alevizo², Kristina Davidson², Christopher DeFelice¹ and Maria Picone¹, ¹TREND Community, Philadelphia, PA, ²Amgen Inc., Thousand Oaks, CA, ³University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy
Background/Purpose: Insights into the everyday burden and management of a disease relies on patient perspectives, and social media groups focused on specific diseases offer a…
Abstract Number: 2356 • ACR Convergence 2024
Baseline Characteristics of Patients with Psoriatic Arthritis Treated with Ixekizumab or Interleukin-23 Inhibitors and Interim Effectiveness Results from an Observational Study in the US
KURT OELKE¹, Emily Edson Heredia², Sarah Ross², Jeffrey Lisse², Jennifer Pustizzi², Ali Sheikhi Mehrabadi², Natalia Bello², Frederick Murphy³, Shikha Singla⁴ and Siba Raychaudhuri⁵, ¹Rheumatic Disease Center, Glendale, WI, ²Eli Lilly and Company, Indianapolis, IN, ³Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁴Medical College of Wisconsin, Milwaukee, WI, ⁵UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, has demonstrated efficacy in treating psoriatic arthritis (PsA) in Phase 3/4 clinical trials…
Abstract Number: 0290 • ACR Convergence 2023
Patient-reported Quality of Life and Working Status Outcomes in Ambulatory Patients with Idiopathic Inflammatory Myopathy
Zhao Peng¹, Yanhong Wang², Ning Liu³, Shuang Zhou⁴, Jiuliang zhao¹, Dong Xu⁵, Mengtao Li⁶, chanyuan wu⁴ and Qian Wang⁴, ¹Peking Union Medical College, Beijing, China, ²Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, HongKong, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: To investigate the health-related quality of life (HR-QoL), work productivity and activity impairment, and associated factors among patients with idiopathic inflammatory myopathy (IIM). Methods:…
Abstract Number: 0648 • ACR Convergence 2023
Incidence and Prevalence of Malnutrition and Its Impact on Mortality in the Multicentre Singapore Systemic Sclerosis Cohort
Bochao Jiang¹, Ennaliza Salazar², Seyed Ehsan Saffari³, Gim Gee Teng⁴, Xin Rong Lim⁵, Sue-Ann Ng², Amelia Santosa⁶, Cassandra Hong² and Andrea Hsiu Ling Low⁷, ¹Ministry of Health Holdings, Singapura, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³Center for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore, ⁴Alexandra Hospital, Department of Medicine, Division of Rheumatology, National University Health System, Singapore, Singapore, ⁵Tan Tock Seng Hospital, Singapore, Singapore, ⁶Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, ⁷Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Gastrointestinal (GI) involvement is common in patients with systemic sclerosis (SSc), and may lead to malnutrition that adversely affects quality of life, morbidity and…

« Previous Page
1
…
7
8
9
10
11
…
30
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].